Results 21 to 30 of about 24,946,579 (254)

Racing for a SARS‐CoV‐2 vaccine

open access: yesEMBO Molecular Medicine, 2021
Graphical Abstract Interview with EMBO Members Özlem Türeci and Uğur Şahin, BioNTech, conducted by science journalist Kai Kupferschmidt.
Özlem Türeci, Uğur Şahin
doaj   +1 more source

Evolutionary Dynamics and Dissemination Pattern of the SARS-CoV-2 Lineage B.1.1.33 During the Early Pandemic Phase in Brazil

open access: yesFrontiers in Microbiology, 2021
A previous study demonstrates that most of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Brazilian strains fell in three local clades that were introduced from Europe around late February 2020.
Paola Cristina Resende   +29 more
doaj   +1 more source

Coronavirus in Continuous Flux: From SARS‐CoV to SARS‐CoV‐2

open access: yesAdvanced Science, 2020
The world is currently experiencing a global pandemic caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which causes severe respiratory disease similar to SARS.
Yetian Dong   +4 more
doaj   +1 more source

Cardiovascular disease in SARS‐CoV‐2 infection

open access: yesClinical & Translational Immunology, 2021
Pre‐existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID‐19 and is strongly associated with poor disease outcomes. However, SARS‐CoV‐2 infection can also trigger de novo acute and chronic cardiovascular disease.
Kei Sato   +5 more
doaj   +1 more source

Subacute thyroiditis after SARS‐CoV‐2 infection

open access: yesClinical Case Reports, 2021
Viral infections are considered as etiologic factors of subacute thyroiditis. The true incidence of subacute thyroiditis, caused by SARS‐CoV‐2 infection, is probably considerable since it is often masked by more dramatic affection of the respiratory ...
Vasiliy I. Semikov   +6 more
doaj   +1 more source

Human monoclonal antibody combination against SARS coronavirus : synergy and coverage of escape mutants [PDF]

open access: yes, 2006
Background: Experimental animal data show that protection against severe acute respiratory syndrome coronavirus (SARS-CoV) infection with human monoclonal antibodies (mAbs) is feasible.
Peiris, Joseph S. M.   +73 more
core   +1 more source

Radiographic findings of SARS‐CoV‐2 infection

open access: yesJournal of the American College of Emergency Physicians Open, 2021
Study objective The 2019–20 coronavirus pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which causes coronavirus disease 2019 (COVID‐19).
Catherine A. Marco   +9 more
doaj   +1 more source

Identification of (20R)-protopanaxadiol from Panax ginseng as a novel anti-SARS-CoV-2 compound. [PDF]

open access: yesFEBS Open Bio
We established a noninfectious BAC‐based SARS‐CoV‐2 replicon that enables antiviral screening under BSL‐2 conditions. Using this platform, we screened 373 food‐derived compounds and identified (20R)‐protopanaxadiol from Panax ginseng as a novel inhibitor of SARS‐CoV‐2 RNA replication, highlighting the value of safe replicon systems for antiviral ...
Takeda M   +4 more
europepmc   +2 more sources

Anti-SARS-CoV-2 S-RBD IgG antibody and anti-SARS-CoV-2 NAb levels.

open access: yes, 2023
Anti-SARS-CoV-2 S-RBD IgG antibody and anti-SARS-CoV-2 NAb levels.
Lugyanti Sukrisman (4808703)   +11 more
core   +1 more source

Maternal SARS‐CoV‐2 infection: The potential vertical transmission of SARS‐CoV‐2 and impact on neonates: A review

open access: yesPediatric Discovery, 2023
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a large, lipid‐enveloped, single‐stranded RNA virus, is a highly contagious virus that caused coronavirus disease 2019 (COVID‐19), declared a pandemic by the World Health Organization on March
Wei Xia, Zhoujie Peng
doaj   +1 more source

Home - About - Disclaimer - Privacy